Intracoronary, No-Reflow, STEMI, Tirofiban
Conditions
Brief summary
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Detailed description
ST-segment-elevation myocardial infarction (STEMI) is most commonly caused by rupture or erosion of an atherosclerotic plaque, resulting in acute occlusion of the coronary artery, and the preferred reperfusion strategy is primary percutaneous coronary intervention (PCI). The no-reflow phenomenon is one of the most common causes of adverse cardiovascular events in patients STEMI. In recent years, mechanical or pharmacological treatment strategies including adjunctive administration of glycoprotein IIb/IIIa inhibitors (GPI) have been proposed in patients with STEMI.
Interventions
DRUGIntracoronary tirofiban
Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
DRUGSaline 0.9%
Patients will receive intracoronary saline 0.9% solution as a control group.
Sponsors
Kafrelsheikh University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old. * Both sexes. * Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
Exclusion criteria
* Treatment with thrombolytic drugs in the previous 24 hours. * Known malignancy. * Thrombocytopenia. * End-stage liver disease. * Cardiogenic shock. * Renal failure with glomerular filtration\<30 ml/min. * Contraindication for the use of tirofiban.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood stream | After treatment (Up to 15 minutes) | Blood stream in coronary artery before and after treatment, including Thrombolysis in Myocardial Infarction (TIMI) flow grade in IRAs, coronary blood flow will be calculated with TIMI frame count method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of major adverse cardiac events | After treatment (Up to 30 days) | Incidence of major adverse cardiac events were recorded. |
Countries
Egypt
Contacts
Primary ContactMohammed A Hammad, MD
Outcome results
None listed